30 Formulations declared Not of Standard Quality as per data provided by states: CDSCO Drug Alert
New Delhi: In line with the 'Not of Standard Quality' data provided by states, the apex drug regulatory body, the Central Drug Standard Control Organisation (CDSCO), in its latest drug safety alert, has flagged 30 medicine batches for failing to qualify for a random sample test for June 2024
The list of drugs declared not of standard quality includes Liquid Paraffin manufactured by Kerala State Drugs and Pharmaceuticals, Losartan Potassium Tablets manufactured by Hindustan Antibiotics, Amloheart-AT [Amlodipine Besylate and Atenolol Tablets] manufactured by Lividus Pharmaceuticals, Bacotil-200 [Cefpodoxime Proxetil Tablets USP ] manufactured by Zenith Healthcare, Oseltamivir Supplied by Kerala Medical Services Corporation, Canditral 100 (itraconazole capsule B.P. 100 mg) manufactured by Glenmark Pharmaceuticals, Lytraco 200 Itraconazole Capsule manufactured by Sterlife Pharma, and others.
A number of factors contributed to the drug samples' failure in the test, such as non-compliance with the IP requirements for the particular drug, failure of the dissolution test, pH, and some assays of the drug test, among others.
Furthermore, the alert noted that NSQ data was not received as per Format and in EXCEL SHEET from State Drugs Licensing Authorities of Rajasthan (PDF format) and Orissa (PDF Format) for the Month of June 2024 as per DCG(I) Circular dated 09.02.2024.
In addition to the above, the alert mentioned, "State Drugs Licensing Authorities of Andhra Pradesh, Arunachal Pradesh, Assam, Bihar, Chhattisgarh,Goa,Gujarat, Haryana, Himachal Pradesh, Manipur, Meghalaya, Mizoram, Nagaland, Odisha, Punjab, Sikkim, Tamil Nadu, Pondicherry,Telangana,Delhi,Uttarakhand, West Bengal, Andaman & Nicobar, Dadar and Nagar Haveli; Daman and Diu, Lakshadweep have not submitted any data in respect of the Not of Standard Quality (NSQ) Alert for the Month of June, 2024 as per DCG(I) Circular dated 09.02.2024."
NOT OF STANDARD QUALITY ALERT FOR THE MONTH OF JUNE – 2024
B. State Laboratories | |||||||
S.No | Product/Drug Name | Batch No. | Manufacturing Date | Expiry Date | Manufactured By | NSQ Result | Reported by CDSCO Laboratory |
1. | Liquid Paraffin IP | EP4032 | 01/24 | 12/26 | Repacked by:- Kerala State Drugs and Pharmaceuticals Ltd, Kalavoor. P.O, Alappuzha | It fails the test of light absorption as per IP | Drugs Testing Laboratory Thiruvananthapuram |
2. | Losartan Potassium Tablets IP 50 mg | HLOA06 | 11/23 | 10/25 | Hindustan Antibiotics Ltd, at II, W.E.A. Faridabad: 121 001(Haryana) R.O, Pimpri, Pune -411 018 | It fails the test ‘Dissolution’ as per IP | Drugs Testing Laboratory Thiruvananthapuram |
3. | Amloheart-AT [Amlodipine Besylate and Atenolol Tablets] | LE223030 | 03/23 | 02/25 | Lividus Pharmaceuticals pvt.Ltd, ikeva, Level2, Agnito Tech park,141 Kandachavadi, Near, Perungudi, OMR, Chennai-600096 | It fails the test ‘Assay’ of Amlodipine Besylate | Drugs Testing Laboratory Thiruvananthapuram |
4. | Bacotil-200 [Cefpodoxime Proxetil Tablets USP ] | ZTB-148 | 03/24 | 02/26 | Zenith Healthcare Ltd works: 388/34, Changodarlnd. Estate, Sarkhej Bavla Highway, Changodar- 382213 (Gujarat) | It fails the test ‘Dissolution’ as per USP | Drugs Testing Laboratory Thiruvananthapuram |
5. | Oseltamivir Cap IP 75 mg | D 0444/24- 25 | Supplied by Kerala Medical Services | The sample does not conform to IP | Drugs Testing Laboratory | ||
Corporation Ltd, Thycaud P.O, Thiruvananthapuram-14 | standard with respect to the ‘Descriptive part’ of hard gelatin capsules | Thiruvananthapuram | |||||
6. | Haridrakhandam | 207/23 | 03/24 | 02/26 | Bhaskaravilasam Vaidyasala, Panayamuttom, Nedumangadu Thiruvananthapuram 695 561 | It fails the test ‘pH’ as per API | Drugs Testing Laboratory Thiruvananthapuram |
7. | Yogarajaguggulu | 209/21 | 03/22 | 3 yrs from the date of mfg | Bhaskaravilasam Vaidyasala, Panayamuttom, Nedumangadu, Thiruvananthapuram 695 561 | It fails the test ‘Alcohol soluble Extractive and pH’ as per API | Drugs Testing Laboratory Thiruvananthapuram |
8. | CANDITRAL 100 (ITRACONAZOLE CAPSULE B.P. 100 MG) | 5230123 | Jan-23 | Jun-25 | GLENMARK PHARMACEUTICALS LTD. | THE SAMPLE DOES NOT COMPLY WITH B P REQUIREMENTS FOR DISSOLUTION TEST | Maharashtra |
9. | Lytraco 200 Itraconazole Capsules 200 mg | SLP-22445 | Feb-23 | Jan-25 | STERLIFE PHARMA PVT. LTD. | THE SAMPLE DOES NOT COMPLY WITH B P REQUIREMENTS FOR DISSOLUTION TEST THE SAMPLE IS OFFICIAL IN B P 2021 THEREFORE THE SAMPLE IS | Maharashtra |
MISBRANDED VIDE SECTION 17(b) AND RULE 96 OF THE DRUGS AND COSMETICS ACT 1940 AND RULES 1945. | |||||||
10. | MONTOR -LC TABLET (MONTELUKAST SODIUM & LEVOCETRIZINE DIHYDROCHLORI DE TABLET I.P.) | B18523001 | Jan-23 | Dec-24 | TORQUE PHARMACEUTICALS PVT. LTD. | THE SAMPLE DOES NOT COMPLY WITH I P REQUIREMENTS FOR DISSOLUTION TEST | Maharashtra |
11. | MONTICET-L Tablets ( Montelukast & Levocetirizine Hydrochloride Tablets) | TP-7581 | Sep-22 | Aug-24 | TICOMA PHARMACIA | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR DISSOLUTION TEST FOR MONTELUKAST. THE SAMPLE IS OFFICIAL IN 1 P 2018 THEREFORE THE SAMPLE IS MISBRANDED VIDE SECTION 17(b) AND RULE 96 OF THE DRUGS AND COSMETICS ACT 1940 AND RULES 1945. | Maharashtra |
12. | Levocetrizine Dihydrochloride & Montelukast Sodium Tablets I.P. Zeemont | T22H370C | Aug-22 | Jul-24 | Bajaj Formulations | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR DISSOLUTION | Maharashtra |
TEST FOR MONTELUKAST. | |||||||
13. | VolKast Kid Syrup 60 ml. | ABS- 2301022 | Jan-23 | Dec-24 | Amentis Biotech Pvt. Ltd. | CONTENT OF MONTELUKAST AND LEVOCETIRIZINE GYDROCHLORIDE IN THE SAMPLE IS LESS (i.e. MONTELUKAST IS 10.50% AND LEVOCETIRIZINE HYDROCHLORIDE IS 71.88% OF THE STATED AMOUNT) THAN THE PERMISSIBLE LIMITS. | Maharashtra |
14. | Levetiracetam Tablets U.S.P.500 Mg (LEVEEG-500) | T23D050A | Apr-23 | Mar-25 | BAJAJ FORMULATIONS | THE SAMPLE DOES NOT COMPLY WITH USP REQUIREMENTS FOR DISSOLUTION. | Maharashtra |
15. | M2 Pan-DSR (Pantoprazole Gastro-resistant & Domperidone Prolonged-release Capsules IP) | CWHC-283 | Oct-22 | Sep-24 | COSWAY PHARMACEUTICALS | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR DISSOLUTION OF PANTOPRAZOLE AT ACID STAGE | Maharashtra |
16. | Omeford - 40 | SNT-220421 | Sep-22 | Aug-24 | SVR HEALTHCARE (A GMP Certified Company) | THE CONTENT OF OMEPRAZOLE IN THE SAMPLE IS LESS (l.e. 40.84% OF LABELLED | Maharashtra |
AMOUNT) THAN THE SCHEDULE V LIMITS | |||||||
17. | COZOL- D(Omeprazole with Domperidone Capsules) | AC1952 | Jul-23 | Jun-25 | ALICON PHARMACEUTICAL PVT LTD | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR OMEPRAZOLE AND DOMPERIDONE CAPSULES FOR THE DISSOLUTION TEST (OMEPRAZOLE). THE SAMPLE IS OFFICIAL IN IP. | Maharashtra |
18. | DRPLAN-DSR (Pantoprazole Gasto-resistant & Domperidone Prolonged-release Capsules IP) | AC2209003A | Sep-22 | Aug-24 | ADDII BIOTECH PVT. LTD. | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR PANTOPRAZOLE AND DOMPERIDONE CAPSULES FOR THE DISSOLUTION TEST (PANTOPRAZOLE) . | Maharashtra |
19. | SOFTOM-D Omeprazole and Domperidone Capsules IP | UD2C- 23252B | Apr-23 | Mar-25 | ULTRA DRUGS PVT. LTD. (UNIT-II) | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR OMEPRAZOLE AND | Maharashtra |
DOMPERIDONE CAPSULES FOR THE DISSOLUTION TEST (OMEPRAZOLE). | |||||||
20. | OMEPRAZOLE & DOMPERIDONE CAPSULES (REMIZOLE-D) | SPC230578 C | Mar-23 | Feb-25 | SALUS PHARMACEUTICALS | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR OMEPRAZOLE AND DOMPERIDONE CAPSULES FOR THE DISSOLUTION TEST (OMEPRAZOLE). | Maharashtra |
21. | PANTOPRAZOLE (EC) & DOMPERIDONE (SR) CAPSULES IP (PANTIAC-DSR) | PTRC-149 | Feb-23 | Jan-25 | IOSIS REMEDIES PVT. LTD. | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR PANTOPRAZOLE AND DOMPERIDONE CAPSULES FOR THE DISSOLUTION TEST (PANTOPRAZOLE) . | Maharashtra |
22. | DYNACID SUSPENSION (aluminium, magnesium & simethicone oral suspension IP.) | BULH23008 | Apr-23 | Mar-25 | Leeford Healthcare Ltd. | 1) THE SAMPLE DOES NOT COMPLY WITH I.P. REQUIREMENTS FOR TOTAL AEROBIC VIABLE | Maharashtra |
COUNT IN TEST FOR MICROBIAL CONTAMINATION. 2) TOTAL AEROBIC VIABLE COUNT OF THE SAMPLE IS 20993128 CFU/GM. (1.P. LIMIT-TOTAL AEROBIC VIABLE COUNT OF THE SAMPLE - NOT MORE THAN 100 CFU/GM | |||||||
23. | ELTHROM-200 (Azithromycin oral suspension IP) 15ML | G-042/5045 | May-23 | Apr-25 | ELFIN DRUGS PVT. LTD. | CONTENT OF AZITHROMYCIN IN THE SAMPLE IS LESS (72.96% OF LABELLED AMOUNT) THAN THE IP LIMIT WITH RESPECT TO ABOVE PROTOCOL. (IP LIMIT-90.0%- 110.0%) | Maharashtra |
24. | Alpracan 0.5 Tablets (Alprazolam Tablets) | T2455 | Oct-22 | Sep-25 | Evolet Pharmaceutical Pvt. Ltd. | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR ALPRAZOLAM TABLETS FOR THE DISSOLUTION TEST WITH RESPECT TO ABOVE PROTOCOL. | Maharashtra |
25. | RABEPP TABLETS (Rabeprazole Sodium Tablets IP) | ATG2K135 | Nov-22 | Oct-24 | ANROSE PHARMA | CONTENT OF RABEPRAZOLE SODIUM IM THE SAMPLE IS LESS (65.04% OF THE LABELLED AMOUNT) THAN THE IP LIMIT WITH RESPECT TO ABOVE PROTOCOL. (IP LIMIT 90.0% - 110.0%) | Maharashtra |
26. | INFI-650 TABLETS (PARACETAMOL TABLETS I.P. 650 mg) | AT-100008 | Dec-22 | Nov-25 | ABARIS HEALTHCARE | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR DISSOLUTION TEST. | Maharashtra |
27. | CUCID-DM | CDMC501 | May-23 | Apr-25 | TULBROS FORMULATIONS | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR DISSOLUTION TEST FOR OMEPRAZOLE IN ACID STAGE. | Maharashtra |
28. | Virpan-40 | T-2306031A | Jun-23 | May-25 | WHITE ENGLE LABORATORIES | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR DISSOLUTION IN BUFFER STAGE. | Maharashtra |
29. | Pantakos-40 (Pantoprazole | CCT231092 B | Sep-23 | Aug-25 | Cent Cure Pvt Ltd. | THE SAMPLE DOES NOT | Maharashtra |
Gastro-resistant Tablets IP ) | COMPLY WITH IP REQUIREMENTS FOR DISSOLUTION IN BUFFER STAGE. | ||||||
30. | Rosumep ASP 10/75mg Capsules | PBWGM04 | Sep-23 | Aug-25 | Pure & Care Healthcare Pvt. Ltd. | THE SAMPLE DOES NOT COMPLY WITH IP FOR THE TEST “RELATED SUBSTANCES – ROSUVASTATIN”. | Maharashtra |
To view the official notice, click the below link:
https://medicaldialogues.in/pdf_upload/state-nsq-alert-for-the-month-of-june-2024-245080.pdf
Also Read:CDSCO may waive cough syrups from testing for export to specific countries
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.